PPMI

1 3	2 CLINICAL DIAGNOSIS AND MA	NAGEMENT QUESTIONNAIRE	. [8	8 8
SUBJECT ID VISIT NO				
INITI	ALS SITE NO VISIT	T DATE MM DD .	YYYY	
1.	To what degree are you confident that this persparkinsonian syndrome (PS) (any condition in a dopaminergic cells in the substantia nigra)?		1.	
	1 = Motor abnormalities that are likely signs of 2 = Motor abnormalities that may be signs of P 3 = Non-specific motor abnormalities (10-49%) 4 = No evidence of parkinsonian motor signs (0	S (50-89%)		
2.	Indicate the following signs on examination that you believe are related to a PS (any condition in which there is neurodegeneration of dopaminergic			
	cells in the substantia nigra). (0 = No, 1 = Yes)		2b.	
	2a. No motor signs consistent with PS2b. Rest tremor		2c.	
	2c. Rigidity 2d. Bradykinesia		2d.	
	2e. Gait disturbances 2f. Other (specify)		2e.	
			2f.	
3.	Indicate the current most likely clinical diagnosisted below (choose one):	is from one of the categories 3	š	
	Disorders expected to have a dopamine tra	nsporter deficit.		
	01 = Idiopathic PD 04 = Corticobasal ganglionic degeneration 05 = Dementia with Lewy bodies 08 = Hemiparkinsonism/hemiatrophy syndrome	11 = Multiple system atrophy 14 = Progressive supranuclear palsy		
	Disorders expected to have no dopamine transporter deficit.			
	02 = Alzheimer disease 03 = Chromosome 17 frontotemporal dementia 06 = Dopa-responsive dystonia 07 = Essential tremor 09 = Juvenile autosomal recessive parkinsonis 10 = Motor neuron disease with parkinsonism 12 = Neuroleptic-induced parkinsonism 97 = Other neurological disorder(s) (specify)	16 = Vascular parkinsonism 17 = No PD nor other neurological		er

PPMI

1 3	2 CLINICAL DIAGNOSIS AND MANAGEMENT QUESTIONNAIRE	8 8
SUB	JECT ID VISIT NO	
4.	Has there been a change in the clinical diagnosis of this subject since the last visit? $(0 = No, 1 = Yes)$	4.
	If Yes (1) to question 4, indicate all factors that have been most influential in your current diagnosis: $(0 = No, 1 = Yes)$	
	4a. Dopamine transporter imaging information	4a.
	4b. Clinical signs	4b.
	4c. Response/lack of response to PD medication	4c.
	4d. Natural history of condition (i.e. rapid progression, lack of progression)	4d.
	4e. Other (specify)	4e.
5.	Has there been a change in the clinical management of this subject since the last visit? $(0 = No, 1 = Yes)$	5.
6.	Current management for this subject includes: (0 = No, 1 = Yes)	
	6a. Management aimed at treating symptoms of PD, including dopamine replacement therapy, anticholinergics, MAO-B inhibitor	6a.
	6b. Enrolled in a treatment trial for PD	6b.
	6c. Management aimed at treating a condition other than PD or PS not associated with a dopamine transporter deficit	6c.
	6d. Additional diagnostic testing	6d.
	6e. No treatment necessary	6e.
		06.
7.	Has the subject seen another neurologist since the last visit? (0 = No, 1 = Yes)	7.
	7a. If yes, what is that neurologist's working diagnosis? (specify)	